Pacira Pharmaceuticals, Inc. (PCRX)
-NasdaqGS | Prev Close: | 29.63 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 34.20 |
|---|
| Beta: | 1.44 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 14.00 - 32.36 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 364,652 |
|---|
| Market Cap: | 979.18M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.98 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira PharmaceuticalsPR Newswire(Mon, Jun 17)
- PACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters toEDGAR Online(Fri, Jun 14)
- 5 Buy Signals From the Health Care Sectorat TheStreet(Tue, Jun 11)
- Postive Interim Data on Pacira's ExparelZacks(Fri, May 31)
- PACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Wed, May 29)
- Pacira Pharmaceuticals, Inc. Announces Positive Interim Analysis of EXPAREL in Femoral Nerve Block for Total Knee ArthroplastyBusiness Wire(Wed, May 29)
- Stocks Shake Off Last Week's Selling, Futures Move Higherat Forbes(Tue, May 28)
- Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2013 Global Healthcare ConferenceBusiness Wire(Tue, May 28)
- PCRX Trading Below Director's Recent Buy Priceat Forbes(Mon, May 20)
- PACIRA PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Wed, May 15)
- SALT 2013: The 5 Best Ideas of the Year Aheadat TheStreet(Fri, May 10)
- Pacira Reports Wider LossZacks(Fri, May 10)
- Pacira Pharmaceuticals Inc. Stock Downgraded (PCRX)at TheStreet(Fri, May 10)
- Pacira Pharmaceuticals Increases Sales but Misses Estimates on Earningsat Motley Fool(Wed, May 8)
- Pacira Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 8)
Press Releases
- Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira PharmaceuticalsPR Newswire(Mon, Jun 17)
- Pacira Pharmaceuticals, Inc. Announces Positive Interim Analysis of EXPAREL in Femoral Nerve Block for Total Knee ArthroplastyBusiness Wire(Wed, May 29)
- Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2013 Global Healthcare ConferenceBusiness Wire(Tue, May 28)
Key Statistics
| Forward P/E (1 yr): | 75.97 |
|---|
| P/S (ttm): | 22.84 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.70 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.43 |
|---|
| Mean Recommendation*: | 1.4 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers worldwide.
View More 
1.35%